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Intraocular Oxygen and Antioxidant Status:
New Insights on the Effect of Vitrectomy and
Glaucoma Pathogenesis
CARLA J. SIEGFRIED AND YING-BO SHUI
 PURPOSE: The purpose of this study was to investigate
correlations of partial pressure of oxygen (pO2) in the
ocular anterior segment of human eyes and aqueous hu-
mor antioxidant levels of ascorbate (AsA) and total reac-
tive antioxidant potential (TRAP) with glaucoma and
vitreous status.
 METHODS: This prospective, cross-sectional study
stratified patients (n[ 288 eyes) by lens and vitreous sta-
tus and the presence of primary open-angle glaucoma for
statistical analyses. Intraocular pO2 concentrations were
measured using a fiberoptic probe in patients at the begin-
ning of planned glaucoma and/or cataract surgery.
Aqueous humor specimens were obtained for antioxidant
analysis of AsA and TRAP.
 RESULTS: Following prior pars plana vitrectomy, pO2
levels were significantly higher than in the reference group
of cataract surgery in the anterior chamber angle (16.2 ±
5.0 vs. 13.0 ± 3.9mmHg;P[ .0171) and in the posterior
chamber (7.6 ± 3.1 vs. 3.9 ± 2.7 mm Hg; P < .0001).
AsA and TRAP levels were significantly lower (1.1 ±
0.4 vs. 1.4 ± 0.5 mM, respectively; 403.3 ±116.5 vs.
479.0 ± 146.7 Trolox units, respectively; P [ .004 and
P[ .024, respectively) in patients after vitrectomy. In pa-
tients with an intact vitreous, neither pO2 nor antioxidant
status correlated with lens status or glaucoma.
 CONCLUSIONS: Increased pO2 and antioxidant depletion
followingvitrectomy suggests an alterationof the intraocular
oxidant-antioxidant balance. Our study links physiologic
factors such as increased pO2 in the anterior chamber angle
and the posterior chamber to decreased antioxidant levels in
aqueous humor following vitrectomy. Oxidative stress/
damage to the trabecular meshwork in such post-
vitrectomy cases may contribute to intraocular pressure
elevation and increased risk of glaucoma. NOTE: Publica-
tion of this article is sponsored by theAmericanOphthalmo-
logical Society. (Am J Ophthalmol 2019;203:12–25. 
2019 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).)
T
HE PRECISE PATHOGENESIS OF PRIMARY OPEN ANGLE
glaucoma has not been fully elucidated. It likely rep-
resents a variety of different pathologies, genetic
predispositions, and contributing environmental factors.
Alterations in the local environment of the trabecular
meshwork (TM), the main pathway for the conventional
outflow of aqueous humor, may also affect its function,
leading to increased intraocular pressure (IOP), an impor-
tant risk factor for glaucoma. Understanding that ocular
structures are ‘‘interconnected’’ is not a new idea. For
example, feedback mechanisms of IOP regulation exist
through nitric oxide synthesis in the TM,1 cyclic mechani-
cal stress yields alterations in conventional outflow facility,2
and TM cells undergo contractile changes, potentially
through rho-kinase-mediated signaling.3 In addition to
these physiologic mechanisms, the concept of intraocular
surgical procedures modifying this environment in a poten-
tially deleterious manner has been previously noted.4,5
Pars plana vitrectomy (PPV) now represents the third
most common intraocular procedure performed in the
United States, with overall rates in the Medicare population
increasing 31% from 2001 to 2012.6 This increase is likely
related to improvements in the safety profile of the proced-
ure, improved success of vision-saving surgical interventions,
decreased use of alternative surgical therapies, and earlier
intervention for non-vision-threatening pathologies
(eg, ‘‘floaterectomy’’). Evaluation of adverse events of this
procedure between 1994 and 2005 indicated, however,
that rates of severe complications such as endophthalmitis,
suprachoroidal hemorrhage, and retinal detachment
remained stable, but rates of less-severe complications such
as glaucoma increased with the prevalence of vitrectomy.7
The vitreous humor is an important ocular structure that
plays a prominent role in maintaining biochemical homeo-
stasis, consuming molecular oxygen (pO2) and protecting
the lens from oxidative damage.8 Shui and colleagues8
found that vitreous gel, in comparison to liquefied vitreous
due to myopia, aging, or surgical removal, has a higher con-
centration of ascorbate (AsA) and consumes pO2 at a faster
rate. Previous studies indicated that antioxidant levels, spe-
cifically AsA and glutathione, are present in high concen-
trations in the vitreous humor.9,10 The discovery of this
role of vitreous gel to maintain the physiologic hypoxic
environment around the lens is important. Initial studies
of patients undergoing long-term hyperbaric oxygen ther-
apy noted a 50% incidence of nuclear cataract
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development within 1 to 3 years.11 In patients undergoing
PPV, it has been observed that a nuclear sclerotic cataract
develops and progresses rapidly in the ensuing 12 to
18 months following vitrectomy, with 37% to 95% of pa-
tients requiring cataract extraction within 2 years.12–18
Vitrector gauge size did not influence these results.19
Increased vitreous liquefaction increases the risk of nuclear
cataract development.20 Identification of increased pO2
levels within the vitreous cavity and at the posterior surface
of the lens following vitrectomy led to the proposal that
increased pO2 exposure leads to oxidative damage to the
lens and nuclear cataract formation.21
Besides the lens, other ocular structures are continuously
exposed to a broad spectrum of pO2 levels, ranging from
hyperoxic to markedly hypoxic. Cells exposed to high
pO2 levels as well as ultraviolet light (eg, corneal epithe-
lium) contain nuclear ferritin,22,23 AsA,24 glutathione,25
superoxide dismutase, and catalase and other antioxi-
dants.26,27 Ocular cells that function at low physiologic
levels of pO2 are unlikely to adapt to altered (ie, higher)
levels of pO2 exposure. Oxygen either is consumed by
functioning cells and/or antioxidants, remains in its
molecular form, or is transformed into other potentially
unstable reactive oxygen species (ROS), capable of
causing damage to RNA, DNA, and proteins. ‘‘Oxidative
stress’’ is defined as an increase over physiologic values in
the intracellular concentrations of ROS, which include
superoxide anions, hydrogen peroxide (H2O2), hydroxyl
radicals, peroxyl radicals, and singlet oxygen. Such ROS
may be detrimental to cellular structures, destroying
membrane lipids as well as structural and enzymatic
proteins and DNA, contributing to cell senescence and
potentially genetically programmed cell death or
apoptosis. Cellular dysfunction results from decreased
mitochondrial respiratory function and protein
degradation.28 Increases in intracellular ROS may be the
result of increased endogenous production by mitochon-
drial respiration or decreased antioxidant capacity.
Increased oxidative stress has been identified as a contrib-
uting factor to the pathogenesis of several age-related
ocular diseases including glaucoma.29,30
Evidence supporting such oxidative damage to the TM
was initially reported by Alvarado and colleagues31 in
1981, as they first suggested that aging and oxidative stress
underlay the degeneration of TM cells in patients with
glaucoma. Cell senescence has been shown to increase
generation of ROS, leading to reduced numbers and func-
tion of mitochondria.32 As a result of this exposure to
oxidative stress, changes occur in TM protein expression
that affect extracellular matrix turnover. For example,
in vivo perfusion of calf anterior segments with H2O2
following depletion of glutathione in the TM increases
outflow resistance.33 TM tissue, compared to corneal and
iris tissues, was found to be most sensitive to oxidative
damage induced by exposure to H2O2.
34 Subsequent studies
provide evidence of oxidative damage and reduced
resistance to oxidative stress in the outflow pathway.35,36
Oxidative damage to DNA is greater in TM cells in
glaucoma patients than in controls37 and correlates with
IOP level and visual field loss.38 Levels of 8-hydroxy-29-
deoxyguanosine (8-OHdG), an established biomarker of
oxidative DNA damage, are significantly higher in both
aqueous humor and sera in patients with glaucoma than
in controls.39 Increased levels of 8-OHdG have also been
found in TM specimens from primary open-angle glaucoma
(POAG) patients.38
Importantly, PPV has also been associated with
increased pO2 exposure to the microenvironment of the
TM and outflow pathways40 and increased risk of
developing open-angle glaucoma in several retrospective
clinical studies41–46 and a recent population-based study.47
The present study was undertaken to provide further under-
standing of the impact of exposure to increased pO2 and/or
its metabolites in the local environment of the aqueous
outflow pathways following vitrectomy. We hypothesized
that increased pO2 in these cases may contribute to alter-
ations of oxidant-antioxidant balance leading to increased
oxidative stress and damage of the TM. To assess these
conditions in human subjects, we measured in vivo levels
of pO2, total reactive antioxidant potential (TRAP)
activity, and AsA levels in aqueous humor in eyes of
patients undergoing glaucoma and/or cataract surgery to
determine associations with glaucoma and vitreous status.
METHODS
 STUDY DESIGN: This prospective, cross-sectional study
was approved by the Institutional Review Board of the
WashingtonUniversity School ofMedicine, in compliance
with the tenets of the Declaration of Helsinki and Health
Insurance Portability and Accountability Act guidelines.
Informed consent was obtained from subjects after the
nature and possible consequences of the study were
explained to them. This study was designed to measure
pO2 distribution within the anterior segment of the eye
and to collect aqueous humor for measurement of antioxi-
dants in patients undergoing cataract and/or glaucoma
surgery in an academic clinical practice. Patients were
excluded from the study if there was evidence of corneal
endothelial dysfunction; ischemic ocular disease, including
diabetic retinopathy, anterior chamber angle closure,
inflammatory or traumatic ocular disease, ocular neoplasia,
requirement for general anesthesia; or monocular status.
 PATIENTS AND PO2 MEASUREMENTS: A complete
general medical and ophthalmic history and comprehen-
sive ophthalmic examinations, including Lens Opacities
Classification System III (LOCS III) analysis for quantita-
tive and qualitative assessment of lens opacities, were
performed prior to surgical intervention. The use of topical
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glaucoma medications within 1 month of the surgical
procedure was verified preoperatively. Patients with a diag-
nosis of POAG (based on optic nerve and visual field
criteria) were classified by glaucoma severity as mild,
moderate, or severe (using Hodapp Parrish Anderson
criteria).48 Central corneal thickness was measured by
ultrasonography (DGH 55 Pachmate, DGH Technology
Inc., Exton, Pennsylvania), and axial length measurements
were recorded (IOLMaster 500, Carl Zeiss Meditec, Inc.,
Jena, Germany) for patients undergoing cataract extrac-
tion. Racial background was based on self-reports, as indi-
cated on a standardized registration questionnaire.
According to our routine surgical protocol, the patient
was placed in a supine position, intravenous sedation was
administered, the eye was prepared and draped, and a lid
speculum was placed. Supplemental pO2 (21%–30%)
was provided through nasal cannulation and separated
from the ocular region by adhesive sterile drape to avoid
any additional pO2 exposure. This technique did not
impact intraocular pO2 measurements as previously re-
ported.21 Blood oxygen saturation was monitored by
continuous pulse oximetry and maintained between
95% and 100%. Topical lidocaine hydrochloride jelly,
2%, was placed on the ocular surface in the preoperative
area. A sub-Tenons injection of 1 to 3 ml of 2% lido-
caine and 0.375% bupivacaine mixture (50/50) was
performed to provide additional local anesthesia as indi-
cated. At the beginning of the planned surgical proced-
ure, a 30-gauge needle was used for entry through the
periphery of a clear cornea into the anterior chamber
(AC) and an Oxylab pO2 optical oxygen sensor probe
(Optode; Oxford Optronix, Oxford, United Kingdom)
was then carefully introduced into the AC without
aqueous humor leakage. The instrumentation was cali-
brated prior to each set of measurements. Under direct
visualization with an operating microscope, the tip of
the flexible fiberoptic probe was positioned for 3 mea-
surements in all patients as described in our previous
studies: 1) underneath the central corneal endothelium,
2) in the mid-AC, and 3) in the AC angle.49,50 In
pseudophakic patients or those scheduled to undergo
cataract extraction, 2 additional measurements were
obtained, 4) at the central anterior lens surface and 5)
in the posterior chamber just behind the iris. These
latter 2 measurements were not made in patients
remaining phakic in order to avoid risk of lens damage.
Approximately 46 seconds (total: <5 minutes) was
required for each set of measurements. In order to
confirm precise and consistent probe positioning and
stabilization of the pO2 level, duplicate testing in the
same locations were performed for verification.
 AQUEOUS HUMOR SPECIMEN COLLECTION: After pO2
levels were measured, the needle entry site in the cornea
was slightly enlarged with a 15-degree blade or side port
instrument, and a sample of aqueous humor (50–100 mL)
was drawn into a 1-mL tuberculin syringe through a 30-
gauge blunt cannula, followed by re-inflation of the AC
volume with balanced salt solution. Care was taken to
avoid contamination of the specimen with blood. The
aqueous humor specimen was immediately transferred to
a sealed tube, placed on dry ice, and transported to storage
in the gas phase of a liquid nitrogen tank until analysis. The
scheduled surgical procedure was subsequently performed
with standard postoperative management, and the patients
were monitored for any complications.
 AQUEOUSHUMORANALYSISOFASCORBATE: AsA con-
centration was quantified in triplicate, based on its ability
to reduce Fe3þ to Fe2þ and the resulting change in the
A525 of complexes of Fe
2þ with 2,299-dipyridyl.51 Assay
modifications enabled the analysis of 10-mL samples, and
a standard curve was used for all measurements, as in our
previous report.8 Gas chromatography-mass spectrometry
studies confirmed the specificity of this colorimetric assay.
Samples of aqueous humor were mixed with a known
amount of carbon 13-labeled ascorbic acid (Omicron Bio-
chemicals, South Bend, Indiana), dried, and then reacted
with N,O-bis(trimethylsilyl)trifluoroacetamide. The sam-
ple was separated on a gas chromatograph (Varian Inc.,
Palo Alto, California) using a 30-m, 0.25-mm-internal
gas chromatography column with a 0.25-mm film (DB-
5 ms column; PJ Cobert Associates Inc., St. Louis,
Missouri), maintained at 808C for 1 minute and then eluted
with a temperature gradient of 808C to 3008C at 158C/min-
ute. The injection port and transfer line were at 2508C and
the source temperature at 2008C of a mass spectrometer
(Finnigan MS SSQ7000; Thermo Electron Corp,
Waltham, Massachusetts) operated in the electron ioniza-
tion mode at 70 eV. AsA concentration was calculated
from the [13C]AsA-to-[12C]AsA ratio. In order to confirm
the specificity of the AsA assay, 2 units of ascorbate oxidase
(AO; A 0157, Sigma Chemical, St. Louis, Missouri) were
added to each of the 10-mL samples and mixed well at
room temperature, and AsA measurements were repeated.
 TOTAL REACTIVE ANTIOXIDANT POTENTIAL: The
TRAP assay is a means to determine the ability of a sample
todestroy chemically generated free radicals.A sample is added
to a solution containing 2,29-azobis(2-amidinopropane)
(ABAP) (Sigma Aldrich, St. Louis, Missouri) and 40 mM
luminol (3-aminophthalhydrazide; Sigma Aldrich). ABAP
combines with pO2 to produce alkyl peroxyl radicals at a
constant rate. In the absence of antioxidant, these radicals
react with luminol to produce light, which is measured in a
scintillation counter. Antioxidants quench luminescence
by reacting with the peroxyl radicals. Because ABAP pro-
duces radicals at a constant rate, antioxidant activity is
measured by the length of time required to quench lumines-
cence.The assay is standardizedusingTrolox, awater-soluble
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vitamin E analog, and reported as ‘‘Trolox units,’’ with 1 unit
equal to the amount of time required to quench lumines-
cence by a sample containing 1 mM Trolox. TRAP was
measured in the aqueous humor samples, and samples were
treated with ascorbate oxidase to remove AsA as described
above. Measurements were then repeated in order to differ-
entiate AsA- from non-AsA-dependent effects on the
composite TRAP value.
 STATISTICAL ANALYSIS: Multivariate regression ana-
lyses were performed with adjustment for all potential
confounding variables (P < .1) including age, sex, race,
medications, and lens status by using SPSS version 24.0
software (Chicago, Illinois). The t-test, one-way
ANOVA with multiple comparison analysis (Bonferroni
correction), and Spearman correlation analyses were
performed using Prism version 8.0 software (GraphPad,
La Jolla, California). Results are expressed as means 6 SD.
P values less than .05 were defined as statistically
significant.
RESULTS
 PATIENT RECRUITMENT AND GROUP ANALYSIS: A
total of 288 eyes of 288 patients participated in the study
between July 2007 and August 2015. Our initial cohort
(July 2007-July 2010) of 112 eyes of 112 patients were
included from a previously published study evaluating
intraocular pO2 measurements.
49 We extended that work
to study a total 288 eyes for pO2, AsA, and TRAPmeasure-
ments after exclusion of 24 eyes due to inadequate
specimen collection. Patients with secondary open-angle
glaucoma (ie, pseudoexfoliative or pigmentary) and
low-tension glaucoma were excluded from this study.
Patient characteristics (Table 1) indicate a greater number
of females and caucasian patients in the study. The cataract
group (CAT) had no history of ocular surgery, glaucoma, or
exposure to ocular glaucoma medications. That group
served as the reference or control group for select statistical
analyses. Consistent with our previously published data,49
patients with a diagnosis of POAG (GL) were subdivided
into patients undergoing glaucoma surgery or combined
cataract and glaucoma surgery (GL/CAT) and pseudo-
phakic patients undergoing glaucoma surgery (GL/IOL).
Patients with a history of vitrectomy who had previously
undergone PPV for vitreoretinal conditions including rheg-
matogenous retinal detachment, epiretinal membrane, and
macular hole but excluding those with proliferative reti-
nopathy made up the VIT group. All these patients were
either pseudophakic or were scheduled to undergo cataract
extraction or glaucoma surgery. Patients in the GL/CAT
and GL/IOL groups were older than those in the VIT group
(P ¼ .0005 and P ¼ .0001, respectively). The GL/IOL
patients were also older than the CAT reference group
patients (P ¼ .005). Subgroup analyses were performed to
identify correlations with race, age, sex, lens, vitreous
status, and ocular medications with pO2 levels and antiox-
idant status. We randomly selected 1 eye for the final data
analysis in patients who had measurements and specimens
taken from both eyes.
 INTRAOCULAR PO2 MEASUREMENTS: Oxygen measure-
ments at five intraocular locations were analyzed by multi-
ple comparison analysis with a Bonferroni correction
(Figure 1). Intraocular pO2 measurements were signifi-
cantly higher after vitrectomy (VIT) than those in the
reference (CAT) group in the AC angle (16.2 6 5.0 mm
Hg vs. 13.0 6 3.9 mm Hg, respectively; P ¼ .0171) and
posterior chamber (7.6 6 3.1 mm Hg vs. 3.9 6 2.7 mm
Hg, respectively; P < .0001). In the GL/IOL (pseudo-
phakic) group, there were significantly higher levels of
pO2 at the anterior lens surface than in the reference group
(8.0 6 4.1 mm Hg vs. 2.5 6 2.4 mm Hg, respectively;
TABLE 1. Patient Demographic Information and Group Descriptions
Groups Group Description Eyes (n) Age (y) F/M
Type of Surgery Race
CAT GL Combined AA CC Other
CAT No prior history of eye surgery
or POAG (reference group)
72 68.0 6 11.4 48/24 72 0 0 26 44 2
GL/CAT POAG undergoing glaucoma surgery
or combined cataract/glaucoma surgery
143 70.4 6 10.8 80/63 35 30 78 39 102 2
GL/IOL Pseudophakic POAG patients
undergoing glaucoma surgery
39 73.8 6 9.0 32/7 0 39 0 10 29 0
VIT Patients who had undergone previous
pars plana vitrectomy
34 63.1 6 13.5 18/16 24 10 0 6 27 1
Total 288 178/110 131 79 78 81 202 5
AA ¼ African American; CAT ¼ cataract; CC ¼ caucasian; F ¼ female; GL ¼ glaucoma; IOL ¼ intraocular lens; M ¼ male; POAG ¼ primary
open-angle glaucoma; VIT ¼ prior vitrectomy.
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P < .0001), in the mid-AC (11.1 6 3.8 mm Hg vs.
8.4 6 3.9 mm Hg, respectively; P ¼ .007), and in the
posterior chamber (5.7 6 3.4 mm Hg vs. 3.9 6 2.7 mm
Hg, respectively; P ¼ .0384).
 ASCORBATE MEASUREMENTS: AsA levels were signifi-
cantly lower in the VIT group (1.1 6 0.4 mM; P ¼ .004)
than in the CAT reference group (1.4 6 0.5 mM). We
further confirmed the fact that AsA is correlated with
prior vitrectomy in a multivariate regression model
(beta ¼ .198; P ¼ .004). AsA levels were increased
in phakic patients with POAG diagnosis (GL/CAT: 1.8
6 0.7 mM; P ¼ .002) as shown in Figures 2A and 2D.
Multivariate regression analyses did not identify any corre-
lations between pO2 and AsA following adjustment for
race, age, sex, lens status, and presence of glaucoma.
 TRAP AND NON-ASA-DEPENDENT TRAP: TRAP and its
component AsA are highly correlated in all human
aqueous humor specimens, confirmed by the marked reduc-
tion of TRAP values in specimens treated with ascorbate
oxidase. We designated the calculated remainder TRAP
value non-AsA-dependent TRAP (non-AsA TRAP) in
our subsequent analyses. As shown in Figures 2B, 2C and
2D, there were significantly lower levels of TRAP after vit-
rectomy (VIT: 403.36 116.5 Trolox units; P ¼ .024) than
in the reference CAT group (479.06 146.7 Trolox units).
Multivariate regression analysis confirmed the correlation
between TRAP and post-vitrectomy status
(beta ¼ .186; P ¼ .007). TRAP is significantly directly
correlated with age (rs ¼ .175; P ¼ .01) as indicated in
Figure 3. The non-AsA TRAP component percentage
was significantly greater in the VIT group (149.9 6 51.9
Trolox units [41.4%]) than in the CAT group (114.5 6
61.9 Trolox units [24.3%]; P ¼ .014). Multivariate regres-
sion also showed correlations between non-AsA TRAP
and vitreous status (beta ¼ .135; P ¼ .05). There were no
differences between the CAT group and the TRAP activity
in both the GL/CAT and the GL/IOL groups. Figure 4
illustrates the comparative contributions of the compo-
nents of TRAP in each group. AsA contributed 76% of
TRAP in the CAT group whereas AsA in the VIT group
contributed only 58%. Multivariate regression analyses
did not indicate any correlations between pO2 and
TRAP in the anterior segment following adjustment for
race, age, sex, lens status, and medication use.
 TOPICAL GLAUCOMA MEDICATIONS: Medications were
classified as beta-blockers (timolol, betaxolol), carbonic
anhydrase inhibitors (dorzolamide, brinzolamide), alpha-2
agonist agents (brimonidine), or prostaglandin analogs
(bimatoprost, latanoprost, travoprost). Fixed combination
agents (brimonidine tartrate/timolol maleate ophthalmic
solution [Combigan], dorzolamide hydrochloride-timolol
maleate ophthalmic solution [Cosopt], and brinzolamide/
brimonidine tartrate ophthalmic suspension [Simbrinza])
were categorized by their individual medication compo-
nents. Because most patients were taking a combination
of medications, each of the agents was analyzed individu-
ally. There was a significant correlation (beta 0.274;
P ¼ .004) between the use of topical carbonic anhydrase
inhibitors (CAIs) and levels of AsA in the aqueous humor
of all glaucoma patients (GL/CAT, GL/IOL). Notably, 69
of 146 patients (47.2%) in this group were taking topical
CAIs as a component of their medical regimen. Four of
35 patients (11.4%) in the VIT group were taking CAI
FIGURE 1. Intraocular pO2measurements (mmHg) were made at the indicated locations (green dots). (A) CAT groups were used as
references for comparison with the other groups. Red numbers indicate P values < .05. (B) GL/CAT indicates diagnosis with
cataract (C) GL/IOL shows glaucoma diagnosis with history of prior cataract surgery. (D) History of prior pars plana vitrectomy.
(E) Comparison among pO2 levels at intraocular locations. Multiple comparisons were made using ANOVA and Bonferroni correc-
tion; P values< .05); error bar indicates mean mm Hg ± SD. ANOVA[ analysis of variance; CAT[ cataract; GL[ glaucoma;
IOL [ intraocular lens; VIT [ vitrectomy.
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agents. After adjustments were made for race, age, sex, and
lens status, no other medication class was correlated with
AsA or TRAP levels. Multivariate regression analysis
correcting for this variable resulted in demonstration of
this drug’s significant impact on AsA levels (Table 2).
DISCUSSION
 OXYGEN MEASUREMENTS AND HOMEOSTASIS: This
prospective, cross-sectional study represents the largest
reported cohort of patients undergoing cataract and/or
glaucoma surgery in which assessments of both intraocular
pO2 levels and aqueous humor antioxidant status were ob-
tained. Precise in vivo measurements of pO2 made by our
colleagues in rabbit and in human vitreous led to these
studies of the anterior segment of the human eye, revealing
consistent pO2 gradients.
21,52,53 Our studies of how pO2
homeostasis is altered by surgical intervention, aging, and
disease may reveal important insights of physiology and
pathology. Because the ocular anterior segment
represents an environment ‘‘protected’’ from direct blood
flow, it provides an ideal site in which to study
homeostatic mechanisms of oxygen metabolism in
addition to oxidant-antioxidant balance. Additionally, by
excluding patients with ischemic retinal disease and the
use of general anesthesia, we separated effects of decreased
retinal blood flow and hyperoxic conditions on intraocular
pO2 levels, respectively.
Increased pO2 in the AC angle of post-vitrectomy
patients (VIT) compared to reference CAT patients may
provide an important source of pro-oxidants leading to
increased oxidative stress in the TM. Elevated pO2 levels
in the TM region and in the posterior chamber may
increase ROS in the aqueous outflow pathway by diffusion
from the ciliary body stroma into the aqueous humor at the
root of the iris. This movement is consistent with the
mechanism of this pathway facilitating movement of
plasma proteins through the TM, as described by Freddo
and colleagues,54 and our previously published hypothesis
regarding the correlation of pO2 levels in the AC and pos-
terior chamber.49 Other body tissues exposed to excess
levels of molecular pO2 have been shown to accumulate
ROS. For example, pulmonary epithelial cells are adapted
to much higher pO2 levels than other cells in the body
(21% O2 or 160 mm Hg), but during prolonged exposure
to levels as high at 40% O2 or greater, increased intracel-
lular ROS leads to pulmonary pO2 toxicity.
55,56
Physiologic conditions for TM cells are relatively hypoxic
as we discovered in the rabbit, monkey, and
human.40,49,53 Exposure of these specialized cells to
elevated pO2 may be ‘‘toxic,’’ leading to decreased TM
cellularity, altered extracellular matrix formation, and
ultimately decreased outflow facility and increased IOP. If
the protective mechanisms of the aqueous humor are
overwhelmed, then oxidative stress and damage may
result. Notably, however, in POAG patients with an
intact vitreous, we did not find increased intraocular pO2
in the TM region or posterior chamber, suggesting this
may not be an important factor in all glaucoma subtypes.
FIGURE 2. Comparison between aqueous humor antioxidant levels and reference groups (CAT black bars). (A) AsA; (B) TRAP;
(C) Non-AsA TRAP; and (D) Mean value ± SD. P values were calculated from unpaired t-tests. Bars are standard deviations.
AsA[ ascorbate; CAT[ cataract; GL[ glaucoma; IOL[ intraocular lens; REF[ reference; TRAP[ total reactive antioxidant
potential; VIT [ vitrectomy.
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Adaptation of ocular structures to specific levels of pO2 is
revealed in studies of oxidative damage and defense. For
example, the basal layer of corneal epithelium is accus-
tomed to high levels of pO2, essentially equivalent to air
with pO2 of 160 mmHg (21% pO2). In contrast, pO2 in in-
ner retinal tissue and the vitreous adjacent to retinal blood
vessels is approximately 20 mm Hg, consistent with other
body tissues.21,57,58 The environment surrounding the
lens is notably hypoxic under normal conditions,
measuring approximately 7 mm Hg at the posterior
surface21 and 3 mm Hg at the anterior and lateral surfaces
of the lens,49 with oxygen consumption by lens cells further
decreasing pO2 within the lens nucleus.
59,60 Extraction of
the natural lens and replacement with an IOL removes
the contributing factor of oxygen consumption by the
lens epithelium, thereby increasing pO2 around the lens,
including the posterior chamber. This pO2 elevation does
not reach the pO2 levels following vitrectomy.
 OCULAR ANTIOXIDANT STATUS: ASCORBATE AND
TRAP: We identified significantly decreased levels of
both AsA and TRAP in aqueous humor of patients who
had undergone vitrectomy (VIT) compared to those in
the reference group (Figure 2). Vitrectomy, independent
of lens status, results in decreased TRAP in comparison
to all other groups analyzed. Vitrectomized eyes also
displayed an increase in non-AsA TRAP compared to
that in the reference group (Figure 4). Interestingly, we
found that POAG patients (GL/CAT, GL/IOL) had higher
levels of AsA and no differences in TRAP than in the refer-
ence group (Figure 2). Lee and colleagues61 also noted
increased aqueous humor AsA in glaucoma patients
compared to cataract surgery controls, whereas Ferreira
and colleagues62 found that AsA levels were decreased in
patients with both POAG and exfoliation syndrome and
that TRAP levels from glaucoma patients were signifi-
cantly lower than those in the cataract group.63
FIGURE 3. Scatterplot diagrams show relationships between (A) AsA and TRAP; (B) TRAP and age; (C) non-AsATRAP and age;
and (D) AsA and age in all cases demonstrating the best linear fit to the data. Analysis used Spearman’s rank-order correlations and
confidence intervals. AsA [ ascorbate; TRAP [ total reactive antioxidant potential.
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Our present study did not support these findings of
decreased AsA in patients with glaucoma compared to
those in cataract controls. Leite and coworkers64 found
that AsA levels were significantly lower in secondary
aqueous obtained from patients with a history of previous
intraocular surgery than in primary aqueous in patients
with glaucoma and cataract. Our separate analysis of
phakic glaucoma patients (GL/CAT) with a history of
intraocular surgery confirmed this finding of decreased
AsA compared to patients without history of surgery
(P ¼ .04; data not shown). Confounding variables such
as frequent use of CAIs in the glaucoma subgroups signifi-
cantly correlated with increased AsA and contributed to
these contradictory findings. In addition, systemic ascor-
bate supplementation was not specifically documented in
our medication review and might have also affected our
results, especially in patients taking high doses of vitamin
C (2 g/day).65
A recently published systematic review and meta-
analysis of oxidant-antioxidant stress markers in glaucoma
demonstrated decreased total antioxidant status in sera and
aqueous humor in glaucoma patients, with the exception of
2 enzymatic antioxidants, superoxide dismutase and gluta-
thione peroxidase.66 These entities may represent a
compensatory protective response to oxidative stress
reflected in this study as non-AsA TRAP. A study of age-
related changes in TRAP plasma levels showed that
TRAP increased with age in both females and males.67
However, in males, levels increased only from 51 to 74
years of age, at which point they were noted to decline.
Increases of antioxidant potential, especially in response
to oxidative stress, were due to unidentified antioxidants
which made up 35% of TRAP in both sexes.
Huang and colleagues68 described ‘‘extreme’’ exposures
to increased pO2 (42.7 6 12.4 mm Hg at the corneal
surface) in patients with Fuchs’ dystrophy,68 another ocular
condition associated with oxidative stress.69 Aqueous
humor levels of AsA and TRAP were significantly
lower than in the cataract reference group (P ¼ .012 and
P ¼ .032, respectively [unpublished data]). In addition,
we previously reported50 increased pO2 in the anterior
segment of patients with African American background
compared to that in caucasians and confirmed in this
expanded study cohort (data not shown). These increased
levels of pO2 did not correlate with differences in antioxi-
dant status, potentially suggesting alternative mechanisms
for this racial group’s increased risk and severity of POAG.
Finally, AsA levels in aqueous humor of patients with
cataract have been shown to decrease with age,70 support-
ing the role of oxidative damage and accumulation of free
radicals in cataract development. We did not identify cor-
relations between AsA and age in this study (Figure 3). We
acknowledge that the oxidant-antioxidant balance in the
eye as reflected in the aqueous humor is undoubtedly highly
complex and requires further study.
 ASCORBATE METABOLISM: Ocular exposure to ultravio-
let and visible light irradiation is greater than any other
organ except skin. Consequently, this organ requires pro-
tective mechanisms against ROS generation. Because the
TM represents the target tissue of glaucoma in the anterior
segment, understanding the role of antioxidants in the
trabecular tissue,71,72 as well as in the aqueous humor in
which it bathes, is critical to our comprehension of
oxidant-antioxidant balance and its role in glaucoma
development. The ‘‘pecking order’’ of aqueous humor anti-
oxidants is affected by both the concentration and electro-
chemical activity of several low molecular weight water
soluble species,73,74 including AsA, L-tyrosine, L-cysteine,
uric acid, and glutathione. Antioxidant enzymes such as
superoxide dismutase, glutathione peroxidase,75 and cata-
lase have also been identified in aqueous humor. In contrast
to nocturnal animals, the corneal epithelium,76,77 lens,78
vitreous,9 and aqueous humor79,80 of diurnal animals
FIGURE 4. Comparison between AsA and non-AsA compo-
nents of TRAP. TRAP was designated as 100%, and the AsA
component (light gray) and the non-AsA-dependent component
(dark gray) are shown as percentages of TRAP values in
each patient group. AsA [ ascorbate; CAT [ cataract;
GL [ glaucoma; IOL [ intraocular lens; REF [ reference;
TRAP[ total reactive antioxidant potential; VIT[ vitrectomy.
TABLE 2. Results of Multivariate Regression Analyses
Evaluating Effect of Topical Glaucoma Medications on
Ascorbate (Asa) in Aqueous Humor
Dependent Variable Independent Variable b P value




Alpha ¼ alpha-2 agonists; AsA ¼ ascorbate; Beta ¼ beta-
blockers; CAI ¼ carbonic anhydrase inhibitors; PG ¼ prosta-
glandin analog.
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contain extremely high levels of AsA compared to that in
plasma.81 Shui and colleagues8 noted that metabolism of
molecular oxygen in the vitreous gel occurs in an AsA-
dependent manner, without an exogenous catalyst and
independent of light, revealing the significance of AsA as
a primary regulator of intraocular molecular oxygen.
AsA is actively concentrated from the plasma through
the sodium-dependent vitamin C (SVC2) transporter
located in the pigmented epithelial cell layer of the ciliary
body with uptake of dehydroascorbic acid (dAsA) through
glucose transporter (GLUT1) receptors in the non-
pigmented epithelial layers.82 AsA secretion into aqueous
humor has been described in animals and humans with sub-
sequent dAsA recycling back to AsA. However, neither
the transporters implicated in the uptake of AsA and its
metabolites nor other transporters of key antioxidants
such as glutathione have been observed to provide specific
information about antioxidant protection of the aqueous
humor and TM.83
A review of published studies led us to propose that ox-
ygen is consumed by AsA in aqueous humor through a 2-
step reaction.84–88 These reactions gradually decrease
oxygen levels as AsA is converted to dAsA:
2O2 þ 2AsA !Fe=Cu 2dAsAðdehydroascorbic acidÞþ2H2O2
2H2O2!Catalase2H2OþO2
Direct in vivo measurements of ROS are problematic
due to their reactivity and transient nature.89 As a result,
quantification of antioxidants is frequently performed as a
surrogate marker of oxidant-antioxidant balance. Using
gas chromatography-mass spectrometry, we measured
dAsA byproducts in ocular fluids and identified 2,3-
diketogulonate and L-threonate (data not shown). The
2,3-diketogulonate reacts with H2O2, producing L-threo-
nate. This provides indirect evidence that H2O2, an impor-
tant ROS, exists in aqueous humor.90
Some investigators have suggested that elevated oxygen
may produce enough H2O2 to exceed the ability of catalase
to remove it,41,91 potentially increasing exposure of the
aqueous outflow pathway to this toxic metabolite. Oxidative
damage or death of TM endothelial cells could result as a
consequence of this exposure, as observed in glaucoma
patients with decreased cellularity of the TM.31,92–94 If
increased oxygen oxidizes AsA and other antioxidants, one
would expect antioxidant molecules to be depleted in the
aqueous humor of patients with elevated pO2. Our findings
of decreased AsA and TRAP levels in eyes after vitrectomy
and IOL implantation support this theory.
 VITRECTOMY AND RISK OF OPEN-ANGLE GLAUCOMA:
Increased pO2 in the AC angle and altered antioxidant sta-
tus may be clinically significant. Alternative mechanisms
of TM damage and physiologic responses may be
represented in these vitrectomized patients compared to
other forms of POAG. As indicated in several retrospective
studies with varying inclusion/exclusion criteria and
follow-up periods, the prevalence (2%–19.2%) of ocular
hypertension and glaucoma following vitrectomy and sub-
sequent lens extraction is inconsistent,42–45 with contrary
conclusions in some studies.46,95,96 The mechanisms of
post-vitrectomy glaucoma likely represent a multifactorial
process with various yet unidentified genetic and/or envi-
ronmental risk factors.
Lelazary and colleagues97 recently completed the
Prospective Retinal and Optic Nerve Vitrectomy Evalua-
tion (PROVE) study. The 3-year data from Patel and
colleagues98 revealed a significant increase in mean IOP
in eyes having undergone both vitrectomy and cataract sur-
gery with IOL implantation compared to baseline (P< .05)
and compared to the fellow eye (P < .05), consistent with
original reports by Chang.41 A recently published retrospec-
tive, population-based cohort study confirmed these find-
ings of increased 10-year risk of POAG in post-vitrectomy
eyes at 10.0% (95% confidence interval [CI]: 3.0–17.0%)
and following vitrectomy combined with scleral buckle at
17.5% (95% CI: 0–34.9%) compared to the nonoperative
group at 1% (95% CI: 1%).47
Of the patients in the VIT group who underwent glau-
coma surgery, 5 of 10 (50%) had a history of controlled
glaucoma prior to PPV surgery and subsequent lens extrac-
tion. The mean time from PPV to glaucoma surgery was
51.3 6 39.4 months (range ¼ 12–118 months). Delayed
onset of elevated IOP and protective effects of the crystal-
line lens have been reported, consistent with our data.42,43
Our findings of further increases of pO2 in the AC angle
and posterior chamber in these cases following cataract
extraction provides additional support for the theory of
prolonged oxidative stress causing TM damage.
Future recruitment of a subgroup of patients who have
undergone PPV and lens extraction without a diagnosis
of ocular hypertension or POAG may provide additional
information. We performed longitudinal assessments of
aqueous and vitreous humor oxidant-antioxidant balance
in an older monkey model of PPV with subsequent lensec-
tomy.40 Our results indicated progressive decrease of both
TRAP and AsA as well as increased 8-OHdG, a marker
of oxidative damage, in both aqueous and vitreous speci-
mens following each surgical procedure.
 ANTIOXIDANT PROPERTIES OF TOPICAL GLAUCOMA
MEDICATIONS: An interesting finding in this study was
the correlation of topical CAIs with AsA levels in aqueous
humor collected from human patients in vivo (Table 2).
CAIs administered topically or systemically to rabbits
resulted in increased concentrations of AsA in the aqueous
of the posterior chamber but not the AC.99 These findings,
confirming prior studies by Becker,100 were noted to be a
reflection of decreased aqueous production and flow in
this region. However, these measurements were based on
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acute therapy with systemic carbonic anhydrase inhibitors,
andmay not be reproduced with chronic topical use, a com-
mon component of glaucoma therapy.
Our findings of significantly higher AsA concentra-
tions in patients taking topical CAIs may represent a po-
tential secondary mechanism of action, as revealed in
the reduction of free radical formation in glaucoma pa-
tients taking topical dorzolamide.101 Timolol, a beta-
blocker, also has been shown to exert direct antioxidant
protection of human endothelial cells in culture.102
Metipranolol, in addition to its active metabolite
desacetylmetipranolol, also exhibits antioxidant proper-
ties in vitro.103 Brimonidine, an alpha-2 adrenergic
agonist, has been shown to exert a neuroprotective effect
on rat retinal ganglion cells in the presence of glutamate,
oxidative and hypoxic stress,104 but no changes in anti-
oxidant levels of the anterior segment. Pre-incubation
of cultured human TM cells with prostaglandin analogs
followed by exposure to H2O2 has been shown to reduce
glaucomatous TM changes in these cells.105 Further
studies of potential antioxidant effects of glaucoma ther-
apies may be warranted.
FIGURE 5. Proposed mechanism for development of post-vitrectomy glaucoma. A: Low levels of pO2 in vitreous cavity, surrounding
clear lens and in anterior chamber (AC) angle. Oxygen diffuses across cornea into the AC and from retinal blood vessels into the
vitreous cavity. B: Following pars plana vitrectomy, pO2 increases in the vitreous cavity, around lens, in AC angle and posterior cham-
ber with development of nuclear sclerotic cataract. C: Following cataract extraction and intraocular lens implantation (IOL), pO2
increases in the AC angle, posterior chamber and mid-A(C) D: Expanded view of AC angle illustrating alterations in aqueous humor
including increased pO2 surrounding lens implant and in AC angle leading to increased reactive oxygen species formation (brown;
ROS) and decreased antioxidants (green). E: Proposed cascade of events following vitrectomy and IOL implantation ultimately lead-
ing to increased intraocular pressure (IOP) and risk of glaucoma. AsA [ ascorbate; GSH [ glutathione; H2O2 [ hydrogen
peroxide; O2
L [ superoxide anion; O2
L2 [ peroxide; OHL [ hydroxyl ion; SOD [ superoxide dismutase; TM [ trabecular
meshwork; TRAP [ total reactive antioxidant potential.
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 STUDY LIMITATIONS: The cross-sectional design of this
study and others identified in our review of published studies
limits our understanding of how responses to oxidative stress
occur over time in a given patient. Future longitudinal ana-
lyses may help to understand questions surrounding progres-
sive TM damage and glaucoma development. As in any
human study, individual patient variation may affect group
mean data analysis. Dependence on a patient’s historical in-
formation regarding medication (eg, antioxidant supple-
ments) and social history (eg, tobacco use) may
significantly alter results, especially with limited sample
size within each of the study groups. Our results did not
confirm previously published findings of decreased antioxi-
dant protection in glaucoma versus cataract patients, despite
similar protocol techniques. Although we designated pa-
tients undergoing cataract surgery as references/controls for
our comparisons, it is important to note that these were not
‘‘normal controls,’’ as they did have a condition(s) associated
with oxidative damage (cataract and aging). Differences in
cataract type and glaucoma severity may have had an impact
on the results aswell as our observation of the effect of specific
glaucomamedications onAsA in aqueous humor. Given our
limited number of VIT subjects, recruitment of additional
post-vitrectomy subjects (with and without glaucoma) could
be informative as vitreoretinal pathology may independently
influence antioxidant levels. Because both patients and spec-
imen quantities were limited, assays of multiple antioxidants
could not be performed for all patients, depending on vol-
umes required. We identified AsA and TRAP as the most
promising agents, given their biochemical reactions with ox-
ygen as thedominantmeasurements of antioxidant potential,
but othermoleculesmay play a significant role in antioxidant
defense (eg, non-AsA TRAP).
CONCLUSIONS
OUR OBSERVATION OF INCREASED PO2 LEVELS IN THE ANTE-
rior segment and decreased levels of AsA and TRAP in the
group of patients who had undergone PPV compared to the
reference group may provide important insights into how
this surgery may increase oxidative stress and glaucoma
risk in select patients. We propose increased intraocular
pO2 levels in these patients could be a potential source of
pro-oxidants for generation of ROS, decreasing antioxi-
dant defenses in the ocular anterior segment (Figure 5).
Further understanding of this surgical intervention’s
impact on oxygen homeostatic mechanisms, antioxidant
balance, and oxidative stress is vital, and these investiga-
tions may lead to future therapies targeted to this specific
population as well as to other individuals afflicted with
this leading cause of irreversible blindness.
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